These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37800841)

  • 1. Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study.
    Lu H; Zheng C; Liang B; Xia X
    Medicine (Baltimore); 2023 Oct; 102(40):e35433. PubMed ID: 37800841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
    Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
    Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis.
    Lu H; Zheng C; Liang B; Xia X
    Curr Radiopharm; 2024; 17(1):46-54. PubMed ID: 38037910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.
    Lu H; Zheng C; Liang B; Xiong B
    BMC Gastroenterol; 2021 Jun; 21(1):256. PubMed ID: 34116638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
    Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
    J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
    Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study on integrative medicine for preventing and treating post-transcatheter arterial chemoembolization].
    Feng YL; Ling CQ; Li B
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jun; 25(6):534-6. PubMed ID: 16025970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: a double-blind, randomized controlled trial.
    Campos GO; de Jesus Martins M; Jesus GN; de Oliveira PRR; Lessa CN; de Oliveira Junior JCMF; de Castro Alves LJS; Alves RL; Módolo NSP
    BMC Anesthesiol; 2019 Aug; 19(1):159. PubMed ID: 31421679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.
    Simasingha N; Tanasoontrarat W; Claimon T; Sethasine S
    World J Gastroenterol; 2023 Feb; 29(5):890-903. PubMed ID: 36816622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis.
    Siriwardana RC; Niriella MA; Dassanayake AS; Liyanage CA; Upasena A; Sirigampala C; de Silva HJ
    BMC Gastroenterol; 2015 Aug; 15():96. PubMed ID: 26239844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F
    Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
    van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
    Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Nagai K; Nakagawa T; Sugawara T; Hanaoka H; Kanai F; Yokosuka O
    Hepatology; 2018 Feb; 67(2):575-585. PubMed ID: 28746788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk.
    Blitz JD; Haile M; Kline R; Franco L; Didehvar S; Pachter HL; Newman E; Bekker A
    Am J Ther; 2012 Sep; 19(5):324-9. PubMed ID: 21519222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization.
    Arslan M; Degirmencioglu S
    Curr Med Imaging Rev; 2019; 15(4):380-385. PubMed ID: 31989907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.